With A CAGR of 5.6%Pulmonary Arterial Hypertension Market Size to Worth USD 9.27 billion by 2026

Summary of Market Information: The global market for Pulmonary Arterial Hypertension (PAH) reached a valuation of USD 6.02 billion in 2018 and is projected to attain USD 9.27 billion by 2026, exhibiting a Compound Annual Growth Rate (CAGR) of 5.6%. PAH is a rare and progressive disorder characterized by elevated blood pressure in the pulmonary arteries, which transport deoxygenated blood from the right ventricle of the heart to the lungs for oxygenation.
In individuals with PAH, symptoms include shortness of breath (dyspnea), especially during physical activity, chest pain, and swelling in ankles and legs. Although the cause of PAH is unknown, symptoms can be managed, but a complete cure remains elusive. Typically affecting women aged 30-60, PAH is expected to see an increase due to the rising prevalence of Chronic Obstructive Pulmonary Disorder (COPD), the third leading cause of death in the United States.
Individuals without treatment may live for an extended period, but addressing PAH is crucial to prevent complications such as heart muscle weakening or failure. Factors such as lifestyle choices, including smoking and alcohol consumption, contribute to the market growth of PAH. However, the high cost of treatment acts as a significant constraint.
Get a sample copy of the Pulmonary Arterial Hypertension Market report: https://www.reportsanddata.com/download-free-sample/2667
Key Report Coverage: The report provides a regional and country-wise assessment from 2016 to 2026, utilizing historical data from 2016-2017, considering 2018 as the base year, and deriving forecasts for 2019-2026. It includes clinical pipeline analysis of regional competitors, demand and supply gap analysis, market share analysis of key industry players, and strategic recommendations for new entrants. The report also offers market forecasts for a minimum of six years across various segments and regional markets, highlighting market trends, drivers, constraints, opportunities, threats, challenges, and recommendations.
Noteworthy Market Trends: The market is witnessing clinical studies for efficient PAH treatment, such as Pilot, BREATHE-1, BREATHE-2, BREATHE-5, and EARLY, aiming to enhance exercise capacity with Bosentan. Increasing technological advances, including the nitric oxide and endothelin pathways, are expected to have synergistic effects. Product development, such as Cicletanine and riociguat, is contributing to market growth.
Recent Developments: In October 2019, Actelion Pharmaceuticals Ltd announced a combination therapy with OPSUMIT (macitentan) and tadalafil, showing hemodynamic improvement and positive effects on functional parameters in PAH patients. Bioelectronic medicine, an emerging approach using device technology to modulate the body's nervous system, is found useful for treating PAH, with Vagus Nerve Stimulation (VNS) showing positive effects.
Key Market Players: Key players in the pulmonary arterial hypertension market include Actelion Pharmaceuticals Ltd, Novartis International AG, Gilead Sciences, Inc., United Therapeutics Corporation, GlaxoSmithKline Plc., Pfizer Inc, Dong-A ST Co Ltd, Bayer HealthCare, Merck Sharp & Dohme Corp, and Arena P.
Market-O-Nomics:
• North America holds the largest market share of 61.4% in 2018, with increased government initiatives and a rise in the number of smokers.
• Hospitals dominate the end-use segment with a 44.4% share in 2018, expected to grow at a CAGR of 5.8%.
• Prostacyclin and Prostacyclin analogs contribute the highest share of 39.2%, acting as a potent vasodilator.
• The Asia-Pacific region is expected to be the highest-growing segment at a CAGR of 7.2%, attributed to increased diseases like HIV and diabetes.
Segmentation: The report segments the market based on product, technology, application, end use, and region, providing revenue forecasts from 2019 to 2026.
• Product Outlook: Prostacyclin and Prostacyclin Analogs, Soluble Guanylate Cyclase Stimulators, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Calcium Channel Blockers, Others.
• Technology Outlook: Cuff-less BP monitoring devices, Ambulatory monitors, Novel technology in smartphones and Bluetooth-enabled tele-monitoring, Tele-monitoring.
• Application Outlook: Early-stage Drug Candidates (Phase I & Phase II), Late-stage Drug Candidates (Phase III & Registration Phase).
• End Use Outlook: Hospital, Clinic.
• Regional Outlook: North America, Europe, Asia Pacific, Middle East & Africa, Latin America.
Explore Trending Reports:
Autoimmune Disease Diagnosis Market-https://www.globenewswire.com/news-release/2020/08/20/2081722/0/en/Autoi...
Spinal Devices Market-https://www.globenewswire.com/en/news-release/2021/01/27/2165180/0/en/Sp...
Protein Expression Market-https://www.globenewswire.com/en/news-release/2021/04/19/2212656/0/en/Pr...
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/2667
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release